Clinical trial
Mannitol Dose Response Study in Cystic Fibrosis
NCT00251056 · Syntara, Industry · Completed
Key facts
| NCT number | NCT00251056 |
|---|---|
| Title | Mannitol Dose Response Study in Cystic Fibrosis |
| Official title | A Phase IIa Randomised, Open Label, Dose Response Study to Determine the Optimum Dose of Dry Powder Mannitol Required to Generate Clinical Improvement In Patients With Cystic Fibrosis |
| Lead sponsor | Syntara, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | mannitol |
| Enrollment | 48 |
| Start date | Oct 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Nov 9, 2005 |
| Last update posted | Aug 29, 2008 |
| Countries | Argentina, Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: